Author

M. Sjostrom

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

F. Y. Feng· 2 shared A. Foye· 1 shared A. Hakansson· 1 shared A. Hanker· 1 shared A. Mukherji· 1 shared A. Ribas· 1 shared A. Sboner· 1 shared A. Vega-Crespo· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Y. Feng

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers

P. Mu, Y. Xu, Z. Wang, M. Sjostrom, S. Deng, C. Wang, N. Jonhson, J. Gonzalez, X. Li, L. Metang, C. Rodriguez, A. Mukherji, G. Wainwright, X. Yu, Y. Yang, , T. Wang

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.

Cancer Discovery · Apr 8, 2024Peer-reviewedCancer Biology

Canonical AREs are tumor suppressive regulatory elements in the prostate

M. A. Augello, X. Chen, D. Liu, K. Lin, A. Hakansson, M. Sjostrom, F. Khani, L. D. Deonarine, Y. Liu, J. Travascio-Green, J. Wu, M. Loda, F. Y. Feng, B. D. Robinson, E. Davicioni, , C. Barbieri

This study identifies canonical AREs as tumor suppressive regulatory elements in prostate cancer, showing their reactivation can induce death in AR+ cancer cells and is linked to better prognosis.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

Evolution of ipsilateral breast cancer decoded by proteogenomics

T. De Marchi, P. T. Pyl, M. Sjostrom, S. E. Reinsbach, S. DiLorenzo, B. Nystedt, L. Tran, G. Pekar, F. Warnberg, I. Fredriksson, P. Malmstrom, M. Ferno, L. Malmstrom, J. Malmstrom, E. Nimeus

This study uses proteogenomics to analyze primary breast cancers and their ipsilateral recurrences, identifying molecular changes linked to recurrence and genomic instability.

bioRxiv · Jul 13, 2022 · PreprintCancer Biology

Autoantibody landscape of advanced prostate cancer

W. S. Chen, W. A. Haynes, R. Waitz, K. Kamath, A. Vega-Crespo, R. Shrestha, M. Zhang, A. Foye, I. Baselga Carretero, I. Garcilazo Perez, M. Zhang, S. G. Zhao, M. Sjostrom, D. A. Quigley, J. Chou, , F. Y. Feng

This study characterizes the autoantibody landscape in metastatic castration-resistant prostate cancer using serum epitope repertoire analysis and identifies novel tumor-specific epitopes.

bioRxiv · May 2, 2020 · PreprintCancer Biology